Jillian H Broadbear

List of Publications by Year
in descending order

62	1,053	394286	454834
papers	citations	19 h-index	30 g-index

62	62	62	1160
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The impact of COVID-19 lockdown on the well-being of clients of a specialist personality disorder service. Australasian Psychiatry, 2022, 30, 235-238.	0.4	3
2	Disjunction in the subjective and objective measurement of co-occurring depression in borderline personality disorder â€“ Implications for diagnosis. Australasian Psychiatry, 2022, 30, 481-485.	0.4	2
3	Emergency department utilisation by patients with a diagnosis of borderline personality disorder: An acute response to a chronic disorder. EMA - Emergency Medicine Australasia, 2022, 34, 731-737.	0.5	5
4	Ten-week Intensive Group Program (IGP) for borderline personality disorder: making the case for more accessible and affordable psychotherapy. Evidence-Based Mental Health, 2021, 24, e1-e1.	2.2	2
5	Confidence of psychiatry trainees in meeting the needs of borderline personality disorder in comparison with schizophrenia. Australasian Psychiatry, 2021, 29, 103985622199265.	0.4	1
6	Discriminative stimulus properties of the 5-HT1A receptor biased agonists NLX-101 and F13714, in rats trained to discriminate 8-OH-DPAT from saline. Behavioural Pharmacology, 2021, Publish Ahead of Print, 652-659.	0.8	1
7	Developments in diagnosis and treatment of people with borderline personality disorder. Current Opinion in Psychiatry, 2020, 33, 441-446.	3.1	7
8	Coronersâ€™ investigations of suicide in Australia: The hidden toll of borderline personality disorder. Journal of Psychiatric Research, 2020, 129, 241-249.	1.5	12
9	Borderline personality disorder and depressive disorder. Australasian Psychiatry, 2019, 27, 573-577.	0.4	32
10	Avoiding Misdiagnosis When Auditory Verbal Hallucinations Are Present in Borderline Personality Disorder. Journal of Nervous and Mental Disease, 2019, 207, 1048-1055.	0.5	25
11	Reviewing the clinical significance of â€˜fear of abandonmentâ€™ in borderline personality disorder. Australasian Psychiatry, 2019, 27, 60-63.	0.4	11
12	An exploration of self-compassion and self-criticism in the context of personal recovery from borderline personality disorder. Australasian Psychiatry, 2019, 27, 56-59.	0.4	17
13	What is the clinical significance of chronic emptiness in borderline personality disorder?. Australasian Psychiatry, 2018, 26, 88-91.	0.4	20
14	Evaluation of a novel risk assessment method for self-harm associated with Borderline Personality Disorder. Australasian Psychiatry, 2017, 25, 460-465.	0.4	6
15	Clinician perspectives on recovery and borderline personality disorder. Journal of Mental Health Training, Education and Practice, 2017, 12, 199-209.	0.3	7
16	Hallucinations in BPD: More prevalent than community sample study suggests?. British Journal of Psychiatry, 2017, 211, 250-251.	1.7	0
17	Consumer perspectives on personal recovery and borderline personality disorder. Journal of Mental Health Training, Education and Practice, 2017, 12, 350-359.	0.3	8
18	Missed diagnosis: The emerging crisis of borderline personality disorder in older people. Australian and New Zealand Journal of Psychiatry, 2016, 50, 1139-1145.	1.3	32

#	Article	IF	Citations
19	Evaluation of changes in prescription medication use after a residential treatment programme for borderline personality disorder. Australasian Psychiatry, 2016, 24, 583-588.	0.4	4
20	Long-Term Antihyperalgesic and Opioid-Sparing Effects of 5-Day Ketamine and Morphine Infusion (â€œBurst Ketamineâ€) in Diabetic Neuropathic Rats. Pain Medicine, 2015, 16, 1781-1793.	0.9	14
21	Risky drug use and effects on sleep quality and daytime sleepiness. Human Psychopharmacology, 2015, 30, 356-363.	0.7	42
22	Dysfunctional overnight memory consolidation in ecstasy users. Journal of Psychopharmacology, 2014, 28, 751-762.	2.0	5
23	Oxytocinergic regulation of endogenous as well as drug-induced mood. Pharmacology Biochemistry and Behavior, 2014, 119, 61-71.	1.3	21
24	Guest editorial. Pharmacology Biochemistry and Behavior, 2014, 119, 1-2.	1.3	3
25	Male and female ecstasy users: Differences in patterns of use, sleep quality and mental health outcomes. Drug and Alcohol Dependence, 2013, 132, 223-230.	1.6	17
26	Disturbed sleep in ecstasy users reported by partners/roommates. Australian and New Zealand Journal of Psychiatry, 2012, 46, 587-588.	1.3	1
27	Modulation of anxiety behavior in the elevated plus maze using peptidic oxytocin and vasopressin receptor ligands in the rat. Journal of Psychopharmacology, 2012, 26, 532-542.	2.0	72
28	Fumaroylamino-4,5-epoxymorphinans and Related Opioids with Irreversible Î¼ Opioid Receptor Antagonist Effects. Journal of Medicinal Chemistry, 2012, 55, 9868-9874.	2.9	8
29	MDMA induces Per1, Per2 and c-fos gene expression in rat suprachiasmatic nuclei. Psychopharmacology, 2012, 220, 835-843.	1.5	3
30	Ecstasy and sleep disturbance: Progress towards elucidating a role for the circadian system. Sleep and Biological Rhythms, 2012, 10, 3-13.	0.5	8
31	Potential Irreversible Ligands for Opioid Receptors. Cinnamoyl Derivatives of Î²-Naltrexamine. Journal of Pharmacy and Pharmacology, 2011, 48, 192-196.	1.2	7
32	Examining the role of oxytocin in the interoceptive effects of 3,4â€methylenedioxymethamphetamine (MDMA, â€˜ecstasyâ€™) using a drug discrimination paradigm in the rat. Addiction Biology, 2011, 16, 202-214.	1.4	32
33	Ecstasy use and selfâ€reported disturbances in sleep. Human Psychopharmacology, 2011, 26, 508-516.	0.7	23
34	Editorial: Preface and Overview Second International MDMA â€˜Ecstasyâ€™ Conference in Australasia: Monash University, Melbourne, Australia. The Open Addiction Journal, 2011, 4, 1-3.	0.5	0
35	Assessing the antidepressant-like effects of carbetocin, an oxytocin agonist, using a modification of the forced swimming test. Psychopharmacology, 2010, 210, 35-43.	1.5	59
36	Acute MDMA administration alters the distribution and circadian rhythm of wheel running activity in the rat. Brain Research, 2010, 1359, 128-136.	1.1	10

#	Article	IF	Citations
37	Neuroendocrine and subjective responses to pharmacological challenge with citalopram: a controlled study in male and female ecstasy/MDMA users. Journal of Psychopharmacology, 2009, 23, 759-774.	2.0	4
38	14Î²-O-Cinnamoylnaltrexone and Related Dihydrocodeinones are Mu Opioid Receptor Partial Agonists with Predominant Antagonist Activity. Journal of Medicinal Chemistry, 2009, 52, 1553-1557.	2.9	12
39	14Î²-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and Related Opioids. Further Examples of Pseudoirreversible Î¼ Opioid Receptor Antagonists. Journal of Medicinal Chemistry, 2009, 52, 6926-6930.	2.9	7
40	Effects of modafinil on simulator driving and selfâ€assessment of driving following sleep deprivation. Human Psychopharmacology, 2008, 23, 681-692.	0.7	33
41	Structural Determinants of Opioid Activity in Derivatives of 14-Aminomorphinones:Â Effect of Substitution in the Aromatic Ring of Cinnamoylaminomorphinones and Codeinones. Journal of Medicinal Chemistry, 2006, 49, 5333-5338.	2.9	20
42	Corticotropin-releasing hormone in nonhuman primates. Frontiers in Bioscience - Landmark, 2006, 11, 2303.	3.0	6
43	Role of Sex and Sex Steroids in Mediating Pituitary-Adrenal Responses to Acute Buspirone Treatment in Sheep. Journal of Neuroendocrinology, 2005, 17, 051017082542002.	1.2	6
44	BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism. European Journal of Pharmacology, 2005, 509, 117-125.	1.7	28
45	Self-administration of methohexital, midazolam and ethanol: effects on the pituitary?adrenal axis in rhesus monkeys. Psychopharmacology, 2005, 178, 83-91.	1.5	23
46	Corticotropin-Releasing Hormone Antagonists, Astressin B and Antalarmin: Differing Profiles of Activity in Rhesus Monkeys. Neuropsychopharmacology, 2004, 29, 1112-1121.	2.8	39
47	Noncontingent and Response-Contingent Intravenous Ethanol Attenuates the Effect of Naltrexone on Hypothalamic-Pituitary-Adrenal Activity in Rhesus Monkeys. Alcoholism: Clinical and Experimental Research, 2004, 28, 566-571.	1.4	21
48	Sex differences in the pituitary-adrenal response following acute antidepressant treatment in sheep. Psychopharmacology, 2004, 171, 450-457.	1.5	13
49	Antidepressants, sex steroids and pituitary?adrenal response in sheep. Psychopharmacology, 2004, 175, 247-55.	1.5	7
50	Self-administration of fentanyl, cocaine and ketamine: effects on the pituitary?adrenal axis in rhesus monkeys. Psychopharmacology, 2004, 176, 398-406.	1.5	70
51	Antalarmin, a putative CRH-RI antagonist, has transient reinforcing effects in rhesus monkeys. Psychopharmacology, 2002, 164, 268-276.	1.5	20
52	Cinnamoyl Derivatives of 7Î±-Amino- and 7Î±-(Aminomethyl)-N-(cyclopropylmethyl)-6,14-endo-ethanotetrahydronororipavines are High-Potency Opioid Antagonists. Helvetica Chimica Acta, 2000, 83, 3122-3130.	1.0	8
53	Glucocorticoid-reinforced responding in the rhesus monkey. Psychopharmacology, 1999, 147, 46-55.	1.5	6
54	3-Alkyl Ethers of Clocinnamox:Â Delayed Long-Term Î¼-Antagonists with Variable Î¼ Efficacy. Journal of Medicinal Chemistry, 1998, 41, 3493-3498.	2.9	19

#	Article	IF	Citations
55	6N-Cinnamoyl-Î²-naltrexamine and its p-nitro derivative. High efficacy Îº-opioid agonists with weak antagonist actions. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 167-172.	1.0	10
56	Opioid agonist effects on mouse writhing after irreversible mu receptor blockade with clocinnamox.. Experimental and Clinical Psychopharmacology, 1995, 3, 323-329.	1.3	7
57	Receptor reserve and affinity of mu opioid agonists in mouse antinociception: correlation with receptor binding. Life Sciences, 1995, 57, 2113-2125.	2.0	38
58	Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on Îº-opioid agonists in the mouse writhing assay. Psychopharmacology, 1994, 115, 311-319.	1.5	126
59	Pharmacokinetic comparison of a combination tablet of enalapril and hydrochlorothiazide with enalapril and hydrochlorothiazide tablets administered together and separately. Biopharmaceutics and Drug Disposition, 1991, 12, 447-455.	1.1	5
60	Role of metabolic risk factors in cardiovascular prognosis of systemic hypertension. American Journal of Cardiology, 1990, 65, H43-H45.	0.7	4
61	The impact of COVID-19 lockdown on the well-being of mental healthcare providers working in a specialist clinic for personality disorder. Australian Psychologist, 0, , 1-7.	0.9	0
62	Assessment of peer-conceptualised, written and led single-session group interventions for carers supporting a person with borderline personality disorder. Advances in Mental Health, 0, , 1-12.	0.3	1